Neuropsychobiology

Research Article

Association of Serotonin Transporter Gene (5-HTTLPR/rs25531) Polymorphism with Comorbidities of Panic Disorder

Tanahashi S.a · Tanii H.a,b · Konishi Y.a · Otowa T.c · Sasaki T.d · Tochigi M.e · Okazaki Y.f · Kaiya H.g · Okada M.a

Author affiliations

aDivision of Neuroscience, Department of Psychiatry, Graduate School of Medicine, Brain Science and Animal Model Research Center, Mie University, Tsu, Japan
bCenter for Physical and Mental Health, Mie University, Tsu, Japan
cDepartment of Neuropsychiatry, NTT Medical Center Tokyo, Tokyo, Japan
dLaboratory of Health Education, Graduate School of Education, The University of Tokyo, Tokyo, Japan
eDepartment of Psychiatry, Teikyo University School of Medicine, Tokyo, Japan
fDepartment of Psychiatry, Koseikai Michinoo Hospital, Nagasaki, Japan
gPanic Disorder Research Center, Warakukai Medical Corporation, Tokyo, Japan

Keywords: 5-HTTLPRAgoraphobiaComorbidityDepressionPanic disorder

Related Articles for ""
Neuropsychobiology 2021;80:333–341
https://doi.org/10.1159/000512699

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: June 02, 2020
Accepted: October 27, 2020
Published online: December 17, 2020
Issue release date: August 2021

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Introduction: Panic disorder (PD) has many comorbidities such as depression, bipolar disorder (BPD), and agoraphobia (AG). PD is a moderately heritable anxiety disorder whose pathogenesis is not well understood. Recently, a tri-allelic serotonin transporter (5-HTTLPR/rs25531) polymorphism was reported to be more sensitive to personality traits compared to the bi-allelic 5-HTTLPR polymorphism. We hypothesized that the 5-HTTLPR/rs25531 polymorphism may lead to a pathological anxious state depending on the presence or absence of a comorbidity in PD. Methods: In this study, we investigated the relationship between comorbidities in PD and tri-allelic 5-HTTLPR polymorphisms. A total of 515 patients with PD (148 males, 367 females) were genotyped, and the Revised NEO Personality Inventory as well as anxiety-related psychological tests were administered. Depression, BPD, and AG were diagnosed as comorbidities. Results: For the tri-allele 5-HTTLPR genotype, a significant interaction effect was found between openness to experience and comorbid depression. Examination of the interaction between AG and the tri-allelic 5-HTTLPR genotype revealed that L’ allele carriers are associated with higher trait anxiety than the S’S’ genotype group in PD without AG. Conclusion: Some anxiety and personality traits can be characterized by the tri-allelic gene effect of 5-HTTLPR. These results suggest that tri-allelic 5-HTTLPR genotypes have genetic effects on the presence of comorbidities of PD.

© 2020 S. Karger AG, Basel



Related Articles:

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Press; 1994.
  2. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol. 2001 Nov;110(4):585–99.
    External Resources
  3. Chen YH, Lin HC. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan. Acta Psychiatr Scand. 2011 Jan;123(1):55–61.
    External Resources
  4. Kaufman J, Charney D. Comorbidity of mood and anxiety disorders. Depress Anxiety. 2000;12(Suppl 1):69–76.
    External Resources
  5. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006 Apr;63(4):415–24.
    External Resources
  6. Sugaya N, Yoshida E, Yasuda S, Tochigi M, Takei K, Otani T, et al. Prevalence of bipolar disorder in panic disorder patients in the Japanese population. J Affect Disord. 2013 May;147(1–3):411–5.
    External Resources
  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington (DC): American Psychiatric Press; 1980.
  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Press; 2013.
  9. Asmundson GJ, Taylor S, Smits JA. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depress Anxiety. 2014 Jun;31(6):480–6.
    External Resources
  10. Cosci F, Mansueto G. Biological and clinical markers in panic disorder. Psychiatry Investig. 2019 Jan;16(1):27–36.
    External Resources
  11. MacKinnon DF, Zamoiski R. Panic comorbidity with bipolar disorder: what is the manic-panic connection? Bipolar Disord. 2006 Dec;8(6):648–64.
    External Resources
  12. Rao S, Han X, Shi M, Siu CO, Waye MM, Liu G, et al. Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder and treatment response: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar;89:214–26.
    External Resources
  13. Schumacher J, Deckert J. Serotonin transporter polymorphisms and panic disorder. Genome Med. 2010 Jun;2(6):40.
    External Resources
  14. Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017 Jun;10(1):28.
    External Resources
  15. Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol. 1998;12(2):115–21.
    External Resources
  16. Mynett-Johnson L, Kealey C, Claffey E, Curtis D, Bouchier-Hayes L, Powell C, et al. Multimarker haplotypes within the serotonin transporter gene suggest evidence of an association with bipolar disorder. Am J Med Genet. 2000 Dec;96(6):845–9.
    External Resources
  17. Rao S, Leung CS, Lam MH, Wing YK, Waye MM, Tsui SK. Resequencing three candidate genes discovers seven potentially deleterious variants susceptibility to major depressive disorder and suicide attempts in Chinese. Gene. 2017 Mar;603:34–41.
    External Resources
  18. Shi M, Hu J, Dong X, Gao Y, An G, Liu W, et al. Association of unipolar depression with gene polymorphisms in the serotonergic pathways in Han Chinese. Acta Neuropsychiatr. 2008 Jun;20(3):139–44.
    External Resources
  19. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000 Jan;5(1):32–8.
    External Resources
  20. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996 Jun;66(6):2621–4.
    External Resources
  21. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov;274(5292):1527–31.
    External Resources
  22. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry. 2006 Mar;11(3):224–6.
    External Resources
  23. Chang HA, Fang WH, Liu YP, Tzeng NS, Shyu JF, Wan FJ, et al. Sex-specific pathways among tri-allelic serotonin transporter polymorphism, trait neuroticism and generalized anxiety disorder. J Psychiatry Neurosci. 2020 Nov;45(6):379–86.
    External Resources
  24. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012 Apr;22(4):239–58.
    External Resources
  25. Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996 Dec;1(6):453–60.
    External Resources
  26. Oo KZ, Aung YK, Jenkins MA, Win AK. Associations of 5HTTLPR polymorphism with major depressive disorder and alcohol dependence: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2016 Sep;50(9):842–57.
    External Resources
  27. Goenjian AK, Bailey JN, Walling DP, Steinberg AM, Schmidt D, Dandekar U, et al. Association of TPH1, TPH2, and 5HTTLPR with PTSD and depressive symptoms. J Affect Disord. 2012 Nov;140(3):244–52.
  28. Schiele MA, Kollert L, Lesch KP, Arolt V, Zwanzger P, Deckert J, et al. Hypermethylation of the serotonin transporter gene promoter in panic disorder – epigenetic imprint of comorbid depression? Eur Neuropsychopharmacol. 2019 Oct;29(10):1161–7.
    External Resources
  29. Chang CC, Chang HA, Fang WH, Chang TC, Huang SY. Gender-specific association between serotonin transporter polymorphisms (5-HTTLPR and rs25531) and neuroticism, anxiety and depression in well-defined healthy Han Chinese. J Affect Disord. 2017 Jan;207:422–8.
    External Resources
  30. Munafò MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet. 2009 Mar;150B(2):271–81.
    External Resources
  31. Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci. 2005 Oct;59(5):517–26.
    External Resources
  32. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999 Apr;174(4):297–303.
    External Resources
  33. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965 Jan;12(1):63–70.
    External Resources
  34. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto (CA): Consulting Psychologists Press; 1983.
  35. Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24(1):1–8.
    External Resources
  36. Costa PT Jr, McCrae RR. Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Odessa (FL): Psychological Assessment Resources, Inc; 1992.
  37. Gudayol-Ferré E, Guàrdia-Olmos J, Peró-Cebollero M, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. J Affect Disord. 2013 Sep;150(3):1082–90.
    External Resources
  38. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilità. Pubbl R Ist Sup Sci Econ Commer Fir. 1936;8:3–62.
  39. Gelernter J. SLC6A4 polymorphism, population genetics, and psychiatric traits. Hum Genet. 2014 Apr;133(4):459–61.
    External Resources
  40. Homberg JR. A mouse model to address unresolved antidepressant issues. Proc Natl Acad Sci USA. 2011 Mar;108(9):3463–4.
    External Resources
  41. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997 Oct–Nov;2(6):457–62.
    External Resources
  42. Asnaani A, Gutner CA, Hinton DE, Hofmann SG. Panic disorder, panic attacks and panic attack symptoms across race-ethnic groups: results of the collaborative psychiatric epidemiology studies. CNS Neurosci Ther. 2009;15(3):249–54.
    External Resources
  43. Minelli A, Bonvicini C, Scassellati C, Sartori R, Gennarelli M. The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. BMC Psychiatry. 2011 Mar;11(1):50.
    External Resources
  44. Beevers CG, Wells TT, Ellis AJ, McGeary JE. Association of the serotonin transporter gene promoter region (5-HTTLPR) polymorphism with biased attention for emotional stimuli. J Abnorm Psychol. 2009 Aug;118(3):670–81.
    External Resources
  45. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, et al. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage. 2009 Apr;45(2):280–5.
    External Resources
  46. Stoltenberg SF, Twitchell GR, Hanna GL, Cook EH, Fitzgerald HE, Zucker RA, et al. Serotonin transporter promoter polymorphism, peripheral indexes of serotonin function, and personality measures in families with alcoholism. Am J Med Genet. 2002 Mar;114(2):230–4.
    External Resources
  47. Rahman MS, Guban P, Wang M, Melas PA, Forsell Y, Lavebratt C. The serotonin transporter promoter variant (5-HTTLPR) and childhood adversity are associated with the personality trait openness to experience. Psychiatry Res. 2017 Nov;257:322–6.
    External Resources
  48. Demiralay C, Husemann J, Koelsch W, Yassouridis A, Wiedemann K, Kellner M. Does 5-HTTLPR genotype influence willingness to participate in panic challenges? Depress Anxiety. 2009;26(2):E68–70.
    External Resources
  49. Inoue K, Kaiya H, Hara N, Okazaki Y. A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. Compr Psychiatry. 2016 Aug;69:132–5.
    External Resources
  50. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593–602.
    External Resources
  51. Roest AM, de Vries YA, Lim CC, Wittchen HU, Stein DJ, Adamowski T, et al.; WHO World Mental Health Survey Collaborators. A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. Depress Anxiety. 2019 Jun;36(6):499–510.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: June 02, 2020
Accepted: October 27, 2020
Published online: December 17, 2020
Issue release date: August 2021

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2021, Vol.80, No. 4

August 2021

Free Supplementary Material

Article

Recommend This
TOP